Developing a Highly Sensitive, MoA-Reflecting ADCC iLite^® Reporter Gene Assay

Regulatory authorities recognize Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) as an important mechanism of action (MoA) for therapeutic antibodies that needs to be quantified and evaluated.

Here, we present a method to evaluate ADCC that overcomes the inherent caveats of using human primary cells as effector cells.

This poster presents data showing iLite assay-ready-cell format minimizes human errors and ensures minimal assay-to-assay variability. Our ADCC bioassays consistently show best-in-class specificity, accuracy, precision, and linearity.